^
Association details:
| Biomarker: | EGFR mutation + PD-L1 negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Published date:
11/25/2020
Excerpt:
Data of 47 patients with EGFR-mutant NSCLC were analyzed. The median (95% confidence interval) PFS in the PD-L1-negative and -positive patient groups were 12.9 (9.7-15.4) months and 9.0 (5.1-12.3) months, respectively (p = 0.029).
DOI:
10.3390/diagnostics10121006
